title: Possible macular exanthema associated with linezolid therapy.
abstract: OBJECTIVE
  To report a case of macular exanthema associated with linezolid therapy.
  
  
  METHODS
  A 54-year-old white man diagnosed as having laryngeal epidermoid carcinoma attended our emergency department because of fatigue, fever, neck pain and a fistulized fixed mass in the right side of the neck with purulent exudation. Treatment with amoxicillin/clavulanic acid 875 mg/125 mg p.o. every 8 hours as empirical therapy was started. Cultures of the exudates from the fistula confirmed the presence of methicillin-resistant Staphylococcus aureus (MRSA). Amoxicillin/clavulanic acid was discontinued and therapy was started with linezolid 600 mg p.o. every 12 hours but 5 days after commencing linezolid the patient came to our emergency room because of generalized erythematous macular eruptions. A diagnosis of severe and generalized macular exanthema induced by linezolid was made. Administration of linezolid was suspended and there was an improvement in the skin lesions and general state of health. The patient was discharged without further symptoms.
  
  
  CONCLUSIONS
  In this case, there was a close temporal correlation between drug exposure and the onset of symptoms. When linezolid was discontinued, the skin lesions resolved quickly and the general condition of the patient improved. Furthermore, linezolid was the only drug added before the cutaneous lesions appeared. It is possible that the adverse reaction was associated with administration of amoxicillin/clavulanic acid. However, the patient had been treated with this antibiotic previously without appearance of any cutaneous reaction. An objective causality assessment revealed that an adverse effect was possible.
  
  
  CONCLUSIONS
  Based on our observations, we conclude that linezolid was the most likely cause of the adverse reaction. Clinicians should be aware of this infrequent but severe reaction.
authors.affiliation: Hospital Pharmacy, Pharmacy Service, Hospital de Sagunto, Valencia, Spain. jborrasb@sefh.es
authors.forename: J
authors.initials: J
authors.lastname: Borrás-Blasco
authors.forename: J M Vicent
authors.initials: JM
authors.lastname: Verge
authors.forename: D
authors.initials: D
authors.lastname: Rosique-Robles
authors.forename: A
authors.initials: A
authors.lastname: Galan-Brotons
authors.forename: E
authors.initials: E
authors.lastname: Casterá
authors.forename: V
authors.initials: V
authors.lastname: Giner-Marco
mesh_terms: D000081:Acetamides / Q000009:adverse effects*; D000890:Anti-Infective Agents / Q000009:adverse effects*; D005076:Exanthema / Q000139:chemically induced*; D006801:Humans; D000069349:Linezolid; D008297:Male; D008875:Middle Aged; D023303:Oxazolidinones / Q000009:adverse effects*
chemical_list: D000081:Acetamides; D000890:Anti-Infective Agents; D023303:Oxazolidinones; D000069349:Linezolid